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Is asthma a problem of microbial ecology?
Asthma is a common respiratory illness affecting approximately 8% of Americans and is char-
acterized by symptoms of wheeze, cough, and shortness of breath. These symptoms are caused
by an inappropriate sensitization to an environmental antigen, or allergen, that leads to airway
inflammation upon reexposure. These responses are typically mediated by allergic T cells (T-
helper 2 [Th2]), which trigger eosinophilic inflammation characteristic of allergic asthma.
Multiple factors contribute to the clinical risk for asthma. A genetic predisposition to allergy
and asthma, called atopy, is a well-established feature in its development. Additionally, envi-
ronmental factors including exposure to allergens, birth delivery mode, diet, and childhood
surroundings may also modify asthma risk.
More recently, the role played by the body’s endogenous microbial communities (micro-
biota) has emerged as a new component to this puzzle. Healthy environmental microbial
exposures not only help the neonatal immune system, including humoral and innate compo-
nents, to mature into an adult-like state after birth but also likely influence immune function
throughout life [1]. Maladaptive microbiota–host interactions have likewise been linked to the
development of disease. A number of studies across a wide variety of illnesses have changed
the way that we regard “pathologic” microbe–host interactions to include the concept of “dys-
biosis,” or dysfunctional microbial communities that contribute to pathology. These dysbiotic
communities fail to adequately perform the normal functions of a healthy microbiota in edu-
cating the immune system, processing dietary components, producing bioactive compounds,
and more, which can profoundly impact host health and disease susceptibility. Dysbiotic gut
and airway microbial communities have been implicated in asthma pathogenesis, indicating
that a comprehensive understanding of the disease will require a detailed understanding of res-
ident bacterial–host interactions.
How could microbial community dynamics promote allergy?
Our microbiota can shape immune responses in numerous ways, including interacting directly
with host immune components, altering metabolic functions, or preventing or promoting
pathogen invasion. Understanding microbial ecology in the context of the host environment is
therefore an increasingly important objective as we seek to understand how microbes may
facilitate allergic inflammation. Even in a stable, nondiseased state, the mucosal environment
in which most commensal microbes reside presents a highly dynamic and complex habitat
with distinct niches and available resources. Further complicating this interaction, microbes in
the mammalian host have the capacity to alter their environment through their interaction
with the host immune system. These microbe-stimulated changes to the environment may be
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an opportunity for bacteria to alter their habitat in their favor, either producing a unique niche
or creating a barrier to competing microbes. Bacteroides fragilis, for example, has recently
been reported to take advantage of the host intestinal immunoglobulin A (IgA) response
to generate a unique niche that enables resistance to displacement by other microbes [2].
Although beneficial to a specific microbe, such immunomodulation may have consequences
for the host.
Like asthma, atopic dermatitis (AD), also called eczema, is a chronic inflammatory skin dis-
ease triggered by Th2 allergic inflammation and is characterized by itchy, dry, and red skin
rashes. Interestingly, AD is associated with a defined skin microbial signature, dominated by
Staphylococcus aureus, that likely plays a role in AD manifestations. S. aureus colonization in
AD has been associated with disease severity [3,4] and may directly promote AD by activating
mast cells through the production of δ-toxin [5] and contributing to Th2 activation [6] (Fig
1F). Inflamed skin, in turn, down-regulates the expression of antimicrobial peptides [7], which
permits further proliferation and persistence of S. aureus, potentially amplifying the course
of disease. Although it is not yet clear what the specific role of such interactions is in allergic
responses, these examples underscore how the factors that govern the microbial ecology of our
microbiota may contribute to asthma and emphasize the potential importance of microbial
communities residing in close association with allergic inflammation in the airway.
Is microbial community composition in the upper airway a risk
factor for asthma?
Early-childhood viral respiratory tract infections have long been recognized to increase the
risk of asthma and contribute to asthma exacerbations [8] (Fig 1E). Bacterial infections have
likewise been implicated in promoting asthma exacerbations, but the roles of airway-coloniz-
ing bacteria in shaping allergic airway responses are only recently being explored. Similar to
the gastrointestinal tract [9], the anatomy of the airway plays an important role in shaping
microbial communities along the respiratory tract. The nasal vestibule is perpetually exposed
to the environment and encounters a constant barrage of debris, microbes, and microbial
products, which presumably contribute to the relatively high density of microbes in the upper
airway. Beyond the nasal vault, air, remaining particles, and microbes aspirated from the oro-
pharynx can pass into the trachea, which is often defined as the beginning of the lower respira-
tory tract. Particles and microbes that are deposited in the lower airway are entrapped in
mucus and returned back up to the esophagus by mucociliary clearance. These natural clear-
ance and relocation mechanisms contribute to shared members but marked differences in
abundance between the upper- and lower-airway bacterial communities [10].
In the upper respiratory tract, specific bacterial taxa have been associated with the develop-
ment of asthma. Multiple studies have reported that neonates colonized with Streptococcus
pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis are at an increased risk for
later diagnosis of asthma compared with uncolonized children [11,12]. The presence of these
asthma-associated microbes in infancy does not reflect mere chance exposure, because their
appearance is associated with acute viral respiratory infections as well as multiple other envi-
ronmental factors including antibiotic usage and daycare attendance [13]. These findings have
been extended to early childhood through 16S rRNA sequencing of nasopharyngeal aspirates
from a cohort of children carefully monitored for respiratory infections during the first 5 years
of life. Confirming earlier reports, these studies found that the same three taxa were predictors
of future diagnosis of asthma [14]. Additionally, the high temporal resolution of sampling
enabled the observation that illness-associated taxa bloom in abundance preceding viral infec-
tion. Perhaps most intriguingly, this study found a time period during early childhood in
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which colonization with Streptococcus, Moraxella, and Haemophilus in the upper airway pre-
dicted later wheeze (a precursor to asthma) in children [14]. A similar “critical window” of
microbial exposure important for later asthma development has also been described in the gut
microbiota and could be scientifically and clinically valuable because it marks a time frame for
potential intervention.
Fig 1. Bacterial communities and metabolites impact multiple stages in the well-established pathway of allergic
inflammation, both offering potentially protective effects (blue arrows) and exacerbating allergic inflammation
(red arrows). (A) SCFAs produced by gut microbiota enhance bone marrow production of dendritic cells and
macrophages with increased phagocytic capacity but reduced ability to stimulate Th2 responses in the lung [33]. (B)
Bacteria found in the airway have been associated with increased markers of Th17 inflammation [20,21,24]. (C)
Microbially derived metabolites may directly stimulate or inhibit [35] Th2 development [31]. (D) Microbially derived
SCFAs found in the healthy gut promote Treg differentiation [34], whereas metabolites like DiHOME produced by
asthmatic gut microbiota inhibit Treg proliferation [31]. (E) Viral respiratory tract infections are associated with
increased risk for asthma and exacerbations [8]. (F) S. aureus colonizes the skin of AD patients depleted of
antimicrobial peptides by allergic inflammation and carries virulence factors that influence the host immune system to
sustain the inflamed state. S. aureus delta toxin, for example, acts on pathways not associated with immunoglobulin E
to stimulate mast-cell degranulation near the site of colonization [3]. Investigating the precise mechanisms by which
bacteria can worsen or mitigate asthma and allergic inflammation will offer novel probiotic candidates and biomarkers
with therapeutic potential. AD, atopic dermatitis; DiHOME, 12,13-dihydroxy-9Z-octadecenoic acid; IL, interleukin;
SCFA, short-chain fatty acid; Th2, T-helper 2; Th17, T-helper 17; Treg, T regulatory cell.
https://doi.org/10.1371/journal.ppat.1007645.g001
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Is there a lung microbiota, and does it play a role in asthma?
The lung itself was regarded as a sterile environment in healthy individuals, maintained by
intrinsic clearance mechanisms, until culture-independent techniques revealed the presence of
a lung microbiota, though at a markedly decreased abundance compared with the upper air-
way [15]. Although studying microbial communities in the lungs is technically challenging
because of low bacterial biomass and the difficulty in acquiring samples [16], differences in the
lung microbiota are associated with asthma [17] and other pulmonary diseases [18]. Airway
microbes may also exert an important effect on asthma even after it is established by modulat-
ing response to therapy [19] or altering the character of inflammatory response [20,21]. More-
over, specific alterations to the lung microbiota have been associated with distinct asthma
phenotypes. For instance, Proteobacteria from lower-airway samples have been associated
with neutrophilic asthma, an endotype of asthma associated with T-helper 17 (Th17) responses
[20,21] (Fig 1B). This ability of airway microbes to alter clinical features of asthma parallels
our evolving understanding of asthma as a highly heterogeneous condition, with many unique
pathophysiologies (referred to as endotypes) that all ultimately lead to asthma’s characteristic
features: airway hyperresponsiveness and obstruction. Whereas the endotype associated with
“classical” allergic asthma is mediated by Th2 inflammation, multiple endotypes have been
described [22].
Although there are multiple clinical studies validating the association between upper- and
lower-airway microbes and asthma, further efforts will be needed to unravel how these bacteria
modify allergic responses. The ability of upper-airway microbes to shape allergic responses has
been investigated in animal models. Inoculation of neonatal mice with nontypeable Haemo-
philus results in transient infection and later susceptibility to worsened allergic airway
inflammation [23]. Exposure to M. catarrhalis has likewise been found to intensify allergic
inflammation in mice through the induction of interleukin 17 (IL-17), resulting in more
recruitment of neutrophils and eosinophils to the lungs [24]. Using these animal models, we
have additionally gleaned that early colonization of the airway by bacteria helps shield mice
from asthma through programmed death ligand 1 (PD-L1)-dependent induction of T regula-
tory (Treg) cells [25]. Microbial colonization in the first 2 weeks of life induces PD-L1 expres-
sion on dendritic cells, which signal Tregs to persist in the immune system. The specific host–
bacterial interactions that promote allergic airway inflammation remain enigmatic, however,
and require additional investigation.
How do gut microbes shape allergic inflammation in the lung?
The vast community of microbes inhabiting the gut has been documented to influence a sur-
prisingly diverse set of diseases, even illnesses that typically involve pathologies at anatomically
distant sites, like multiple sclerosis [26,27] and arthritis [28]. The influence of gut microbes on
pulmonary diseases has been referred to as the “gut–lung axis,” and several studies have impli-
cated intestinal microbial communities in the pathogenesis of asthma, particularly in early
childhood. Although multiple pathways probably underlie the communication between gut
microbial communities and the lung in asthma [29,30], microbiota-derived metabolites are
emerging as a particularly compelling example.
For instance, the composition of neonatal gut microbial communities can acquire configu-
rations with decreased representation of Akkermansia, Bifidobacterium, and Faecalibacterium,
which predict later development of allergy and asthma [31]. Coculture of sterile fecal extracts
generated from these dysfunctional microbial communities with human lymphocytes pro-
motes the development of allergy-inducing Th2 cells while inhibiting the differentiation of
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007645 April 25, 2019 4 / 7
Treg cells, directly implicating microbially derived products in conferring susceptibility to
allergic disease (Fig 1C and 1D).
Furthermore, investigators studying the Canadian Healthy Infant Longitudinal Develop-
ment cohort identified four taxa in neonates—Faecalibacterium, Lachnospira, Veillonella, and
Rothia (FLVR)—that corresponded to later protection from asthma. When these four bacteria
were supplemented to an asthmatic gut microbial community in gnotobiotic mice, animals
receiving FLVR taxa experienced protection from allergic airway inflammation compared
with controls that received no supplementation. Colonization with FLVR also corresponded to
increases in the amounts of fecal acetate [32], a short-chain fatty acid (SCFA) known to protect
from asthma [33]. Differences in SCFAs have been observed in 3-month-olds who displayed
atopy and wheeze at 1 year [32]—symptoms that are predictive of later asthma. Moreover,
SCFAs are known to influence Treg differentiation and function (e.g., [34]), which may con-
tribute to asthma. Additionally, SCFAs generated by the gut microbiota have also been demon-
strated to alter dendritic-cell recruitment and function within the lungs and reduce Th2
inflammation [33,35] (Fig 1A). Intriguingly, FLVR were protective only when present during
the first 100 days of life, which suggests a critical window of gut colonization during which
exposure to key organisms can prevent later disease. This phenomenon is similar to the critical
window observed for airway colonization [14], suggesting that exposure to particular micro-
bial communities during a crucial moment in early life results in a lasting restructuring of the
host’s immune system.
Concluding remarks
Our growing appreciation for the role of commensal microbes in human health has placed the
microbiota among the important factors contributing to asthma pathogenesis. Although the
mechanisms by which endogenous bacterial communities affect asthma are still being eluci-
dated, the enticing potential for therapeutic interventions will ensure continued interest and
exploration on the influence of microbial communities on allergic diseases. Perhaps most
compellingly, unlike host genetics and environmental exposures, which are known risk factors
for allergic diseases, the microbiota presents a more easily modifiable feature in asthma devel-
opment. One potential approach is to design probiotics that alter the composition or function
of respiratory or gastrointestinal microbial communities in at-risk children. The promise of
this approach relies on identifying individuals who would benefit from a probiotic interven-
tion and exploiting the “critical window” in early life, during which microbial exposures can
shape later asthma [14,31,32]. However, before we can benefit from microbiota-directed thera-
peutics in asthma, it is necessary to further define the mechanism(s) by which gut and airway
microbes protect from the disease and to assist the identification of therapeutic candidates and
biomarkers. Together, these new insights signify the beginning of a novel paradigm to under-
stand the etiology of asthma as an emergent condition resulting from the codevelopment of
microbial communities and host immunity. Innovations from this research may lead to trans-
formative advances in our understanding and treatment of asthma.
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